Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years

Pediatric Infectious Disease Journal

Volumn 15, Issue 8, 1996, Pages 687-692

  Johnson, Candice E ^a,d   Kumar, Mary Lou ^a   Whitwell, Judy K ^a   Staehle, Brenda O ^c   Rome, Leonard P ^b   Dinakar, Chitra ^a   Hurni, William ^c   Nalin, David R ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Measles vaccine; mumps vaccine; rubella vaccine; vaccine immunogenicity

Indexed keywords

IMMUNOGLOBULIN M; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; MUMPS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVACCINATION; RUBELLA; SCHOOL CHILD;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEASLES VACCINE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; MUMPS VIRUS; PROSPECTIVE STUDIES; RUBELLA VACCINE; RUBELLA VIRUS; VACCINES, COMBINED;

EID: 0029761115     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199608000-00010     Document Type: Article

References (16)

1. Baughman AL, Williams WW, Atkinson WL, Cook LG, Collins M. The impact of college prematriculation immunization requirements on risk for measles outbreaks. JAMA 1994;272: 1127-32.
2. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. Measles vaccine immunogenicity in 6- versus 15-month old infants born to mothers in the measles vaccine era. Pediatrics 1994;93:939-43.
3. Forsey T, Heath AB, Minor PD. The first international standard for anti-measles serum. Biologicals 1991;19:237-41.
4. Shehab ZM, Brunell PA. Epidemiological standardization of a test for susceptibility to mumps. J Infect Dis 1984;149:810-2.
5. Parkman PD, Mundon FK, McCown JM, Bruescher EL. Studies of rubella. II. Neutralization of the virus. J Immunol 1964;93:608-17.
6. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990;162:1036-42.
7. Samb B, Aaby P, Whittle HC, et al. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995;14:203-9.
8. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981;3:251-60.
9. Olsha M, Mendelson E, Shohat T, Cohen D, Duvdevani P, Lerman Y, Danon YL. Measles immunity in Israeli young adults: effects of second immunization at 18 years of age. Isr J Med Sc 1994;30:596-9.
10. Christenson B, Böttiger M. Measles antibody comparison of long term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994;12:129-33.
11. Wittier RR, Veit BC, McIntyre S, Schydlower M. Measles revaccination response in a school-age population. Pediatrics 1991;88:1024-30.
12. King JC, Lichenstein R, Feigelman S, Luna C, Permutt TJ, Patel J. Measles, mumps and rubella antibodies in vaccinated Baltimore children. Am J Dis Child 1993;147:558-60.
13. Kelly PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections: a national serosurvey of US Army recruits. JAMA 1991;266:2724-9.
14. Christenson B, Bottinger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine 1994;12:41-5.
15. Centers for Disease Control. Mumps: United States, 1985-1988. MMWR 1989;38:101-5.
16. Briss PA, Fehrs LJ, Parker RA, et al. Sustained transmission of mumps in a highly vaccinated population. J Infect Dis 1994;169:77-82.